SPNT:NYSESiriusPoint Ltd. Analysis
Data as of 2026-09-01 - not real-time
$24.19
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
At $24.19, SiriusPoint Ltd. shows no decisive moving-average alignment, leaving the trend neutral. The last 30 days have lost 1.9%. Relative strength is 55.6 — neutral — and the MACD signal is bullish. Price has been bracketed by support at $22.36 and resistance at $24.47.
On valuation the read is undervalued — earnings multiple of 6.0 versus a 16.9 sector average, below the peer group. Analyst price targets sit 14.4% above the current price.
On a 1-10 scale the risk profile lands at 4 — moderate. With 30-day volatility of 32.5%, a beta of 0.05 and a maximum drawdown of 14.7%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: buy, at a conviction of 7 out of 10.
On valuation the read is undervalued — earnings multiple of 6.0 versus a 16.9 sector average, below the peer group. Analyst price targets sit 14.4% above the current price.
On a 1-10 scale the risk profile lands at 4 — moderate. With 30-day volatility of 32.5%, a beta of 0.05 and a maximum drawdown of 14.7%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: buy, at a conviction of 7 out of 10.
Top Market Events
SiriusPoint Ltd. has reported its second-quarter 2026 results, with revenue of US$744.1 million and net income of...HAMILTON, Bermuda, July 24, 2026 GLOBE NEWSWIRE -- SiriusPoint Ltd.HAMILTON, Bermuda, July 29, 2026 GLOBE NEWSWIRE -- SiriusPoint Ltd.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 6/10
Key Factors
- Trading above the 200-day average of 22.21
- MACD momentum is positive
- RSI at 55.6 is in neutral territory
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- P/E of 6.0 versus sector average of 16.9
- Trading above the 200-day average of 22.21
- Analyst targets imply +14.4% versus the current price
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- P/E of 6.0 versus sector average of 16.9
- Analyst targets imply +14.4% versus the current price
- Profit margin of 16.8% is healthy
Key Metrics & Analysis
Financial Health
Revenue Growth-0.50%
Profit Margin16.85%
P/E Ratio6.0
ROE23.07%
ROA2.18%
Debt/Equity30.79
P/B Ratio1.2
Op. Cash Flow$265.9M
Free Cash Flow$204.2M
Industry P/E16.9
Technical Analysis
TrendNeutral
RSI55.6
Support$22.36
Resistance$24.47
MA 20$23.56
MA 50$24.07
MA 200$22.21
MACDBullish
VolumeDecreasing
Fear & Greed Index93.05
Valuation
Fair Value$22.25
Target Price$27.67
Upside/Downside14.37%
GradeUndervalued
TypeValue
Risk Assessment
Beta0.05
Volatility32.52%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.